Your browser doesn't support javascript.
loading
Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries.
Kobayashi, Taku; Hisamatsu, Tadakazu; Suzuki, Yasuo; Ogata, Haruhiko; Andoh, Akira; Araki, Toshimitsu; Hokari, Ryota; Iijima, Hideki; Ikeuchi, Hiroki; Ishiguro, Yoh; Kato, Shingo; Kunisaki, Reiko; Matsumoto, Takayuki; Motoya, Satoshi; Nagahori, Masakazu; Nakamura, Shiro; Nakase, Hiroshi; Tsujikawa, Tomoyuki; Sasaki, Makoto; Yokoyama, Kaoru; Yoshimura, Naoki; Watanabe, Kenji; Katafuchi, Miiko; Watanabe, Mamoru; Hibi, Toshifumi.
Afiliação
  • Kobayashi T; Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
  • Hisamatsu T; The Third Department of Internal Medicine, Kyorin University School of Medicine, Mitaka, Japan.
  • Suzuki Y; Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan.
  • Ogata H; Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Tokyo, Japan.
  • Andoh A; Department of Gastroenterology, Shiga University of Medical Science, Otsu, Japan.
  • Araki T; Department of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, Tsu, Japan.
  • Hokari R; Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan.
  • Iijima H; Department of Gastroenterology and Hepatology, Graduate School of Medicine, Osaka University, Suita, Japan.
  • Ikeuchi H; Department of Inflammatory Bowel Disease, Division of Surgery, Hyogo College of Medicine, Nishinomiya, Japan.
  • Ishiguro Y; Department of Gastroenterology and Hematology, Hirosaki National Hospital, Hirosaki, Japan.
  • Kato S; Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
  • Kunisaki R; Inflammatory Bowel Disease Center, Yokohama City University Medical Center, Yokohama, Japan.
  • Matsumoto T; Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Morioka, Japan.
  • Motoya S; IBD Center, Sapporo-Kosei General Hospital, Sapporo, Japan.
  • Nagahori M; Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
  • Nakamura S; Department of Inflammatory Bowel Disease, Hyogo College of Medicine, Nishinomiya, Japan.
  • Nakase H; Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Tsujikawa T; Department of Gastroenterology and Hepatology, Higashi-Ohmi General Medical Center, Higashiomi, Japan.
  • Sasaki M; Division of Gastroenterology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
  • Yokoyama K; Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
  • Yoshimura N; Division of Gastroenterology, Department of Medicine, Tokyo Yamate Medical Center, Tokyo, Japan.
  • Watanabe K; Department of Intestinal Inflammation Research, Hyogo College of Medicine, Nishinomiya, Japan.
  • Katafuchi M; Medical Affairs, Medical, AbbVie GK, Tokyo, Japan.
  • Watanabe M; Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
  • Hibi T; Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
Intest Res ; 16(2): 168-177, 2018 Apr.
Article em En | MEDLINE | ID: mdl-29743830
ABSTRACT
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international educational program that aims to explore questions commonly raised by clinicians about various areas of IBD care and to consolidate available published evidence and expert opinion into a consensus for the optimization of IBD management. Given differences in the epidemiology, clinical and genetic characteristics, management, and prognosis of IBD between patients in Japan and the rest of the world, this statement was formulated as the result of literature reviews and discussions among Japanese experts as part of the IBD Ahead program to consolidate statements of factors for disease prognosis in IBD. Evidence levels were assigned to summary statements in the following categories disease progression in CD and UC; surgery, hospitalization, intestinal failure, and permanent stoma in CD; acute severe UC; colectomy in UC; and colorectal carcinoma and dysplasia in IBD. The goal is that this statement can aid in the optimization of the treatment strategy for Japanese patients with IBD and help identify high-risk patients that require early intervention, to provide a better long-term prognosis in these patients.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article